相关实验视频
Updated: Feb 20, 2026

08:53
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
821
通过使用活性炭来解决比瓦利鲁丁对纤维素测试的干扰
Jia Du1,2, Haiyan Liu1, Xiaohui Liu1,2
1Clinical Laboratory, Wuhan Asia General Hospital Affiliate to Wuhan University of Science and Technology, Wuhan, China.
Journal of clinical laboratory analysis
|February 18, 2026
概括
像比瓦利鲁丁这样的直接血栓激素抑制剂可以导致虚假的低纤维素原体结果. 活性炭有效地去除了比瓦利鲁丁,解决了它在纤维素原测试中的干扰.
科学领域:
- 临床化学 临床化学
- 血液学 血液学 血液学
- 生物化学 生物化学
背景情况:
- 直接血栓抑制剂 (DTI) 可以干扰实验室检测.
- 比瓦利鲁丁对纤维素原测试的影响需要彻底调查.
- 准确的纤维素素测量对于患者管理至关重要.
研究的目的:
- 为了评估比瓦利鲁丁对纤维素素测试的干扰.
- 评估活性炭在缓解这种干扰方面的有效性.
主要方法:
- 血样本中添加了不同度的比瓦利鲁丁.
- 用克劳斯试验和免疫试验测量纤维素水平.
- 在活性炭处理之前和之后,分析了活性部分血栓形成时间 (APTT) 和纤维素原.
主要成果:
- 免疫测试显示,比瓦利鲁丁没有干扰.
- 克劳斯测试显示,纤维素原的结果显著下降,取决于度.
- 活性炭有效地去除了比瓦利鲁丁,恢复了纤维素原水平到基线.
结论:
- 比瓦利鲁丁在纤维素测试中的干扰是测试依赖的.
- 活性炭是一种可行的方法,可以消除比瓦利鲁丁干扰.
- 这一发现支持在接受比瓦利鲁丁治疗的患者中进行准确的纤维素原测试.
相关概念视频
Venous Thrombosis III: Interprofessional Care
392
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
392
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Clot Retraction and Fibrinolysis
9.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.4K
Coagulation
1.5K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.5K

